Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1993 2
1995 1
1996 3
1997 3
1999 2
2000 2
2001 7
2002 4
2003 2
2004 10
2005 4
2006 16
2007 16
2008 17
2009 20
2010 25
2011 26
2012 37
2013 38
2014 36
2015 42
2016 33
2017 40
2018 63
2019 17
2020 45
2021 27
2022 30
2023 37
2024 35
2025 34
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

631 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy.
Strawser CH, Chakraborty B, Michaud D, Chang CY, Dent S, Jain V, Tolaney SM, Weinhold K, McAllister SS, Miller KE, Steadman K, Arvai S, Hocke E, Agrawal Y, Perou CM, Goel S, McDonnell DP, Guerriero JL, Sammons S. Strawser CH, et al. Among authors: perou cm. Clin Cancer Res. 2026 May 13. doi: 10.1158/1078-0432.CCR-25-0946. Online ahead of print. Clin Cancer Res. 2026. PMID: 42126533
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer.
Howard FM, Li A, Kochanny S, Sullivan M, Flores EM, Dolezal J, Khramtsova G, Jain-Liu S, Medenwald R, Saha P, Fan C, McCart L, Watson M, Teras LR, Bodelon C, Patel A, Symmans WF, Partridge AH, Carey L, Olopade OI, Stover D, Perou C, Yao K, Pearson AT, Huo D. Howard FM, et al. Among authors: perou c. medRxiv [Preprint]. 2026 May 5:2026.04.23.26351499. doi: 10.64898/2026.04.23.26351499. medRxiv. 2026. PMID: 42078387 Free PMC article. Preprint.
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.
Matikas A, Tzoras E, Sarafidis M, Sifakis EG, Bjöhle J, Barnekow E, Margolin S, Isaksson-Friman E, Kessler LE, Zouzos A, Johansson H, Hellström M, Agartz S, Grybäck P, Salgkamis D, Zerdes I, Wang K, Hartman J, Acs B, Sun W, Boyaci C, Villacampa G, Pascual T, Gavila J, Prat A, Perou C, Brandberg Y, Bergh J, Hatschek T, Foukakis T. Matikas A, et al. Among authors: perou c. Nat Commun. 2026 Apr 8;17(1):3403. doi: 10.1038/s41467-026-71452-6. Nat Commun. 2026. PMID: 41951647 Free PMC article. Clinical Trial.
Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer.
Gao A, Khatri PH, Ma G, Liu P, Fernandez-Martinez A, Donahue K, Wang Y, Kim EJ, Hu M, Liu F, Zhou J, Chan NT, Yang X, Welch Schwartz R, Ong IM, Burkard ME, Wisinski KB, Perou CM, Dinh HQ, Xu W. Gao A, et al. Among authors: perou cm. Cancer Res. 2026 Jul 2;86(13):3287-3308. doi: 10.1158/0008-5472.CAN-25-4701. Cancer Res. 2026. PMID: 41886605 Free PMC article.
Transcriptomic profiling of mouse mammary tumors enables prognostic and predictive biomarker discovery for human breast cancers.
Sutcliffe MD, Mott KR, Yilmaz-Swenson T, Felsheim BM, Lobanov AV, Michmerhuizen AR, Rädler PD, Okumu DO, He X, Pfefferle AD, Dance-Barnes S, East MP, Hollern DP, Elston TC, Johnson GL, Perou CM. Sutcliffe MD, et al. Among authors: perou cm. bioRxiv [Preprint]. 2026 Mar 3:2026.02.28.707759. doi: 10.64898/2026.02.28.707759. bioRxiv. 2026. PMID: 41835398 Free PMC article. Preprint.
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).
Pascual T, Vidal M, Cejalvo JM, Vega E, Sanfeliu E, Villacampa G, Ganau S, Parreño AMJ, Zamora E, Miranda I, Delgado A, Bermejo B, Seguí E, Brasó-Maristanty F, de la Cruz-Merino L, Juan M, Galván P, Gonzàlez-Farré X, Chillara S, Villagrasa P, Pfefferle AD, O'Connell CE, Ferrero-Cafiero JM, Oliveira M, Perou CM, Prat A. Pascual T, et al. Among authors: perou cm. Nat Commun. 2026 Feb 16;17(1):2817. doi: 10.1038/s41467-026-69222-5. Nat Commun. 2026. PMID: 41698899 Free PMC article. Clinical Trial.
MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9+ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer.
Smith AJ, Schrank Z, Guan N, Pedroza DA, Calderon S, Yuan X, Zhao N, Gabriel Z, Gao Y, Rivas C, Liu F, Serody JS, Perou CM, Earp HS, Rosen JM. Smith AJ, et al. Among authors: perou cm. bioRxiv [Preprint]. 2026 Feb 6:2026.02.04.703648. doi: 10.64898/2026.02.04.703648. bioRxiv. 2026. PMID: 41676642 Free PMC article. Preprint.
Proteotranscriptomic Dissection of Breast Cancer T Cell States Identifies CD103+ Tfh-derived Cytotoxic Cells Linked to Immunotherapy Response.
Al-Eryani G, Van Der Leij S, Masle-Farquhar E, Chan CL, Harvey K, Wu SZ, Roden D, Wang T, Reeves J, Yeung BZ, Goodnow CC, Ma CS, Perou CM, Hacohen N, Al'Khafaji AM, Nilsson M, Lundeberg J, Batten M, Junankar S, Swarbrick A. Al-Eryani G, et al. Among authors: perou cm. Res Sq [Preprint]. 2026 Jan 7:rs.3.rs-8394722. doi: 10.21203/rs.3.rs-8394722/v1. Res Sq. 2026. PMID: 41542042 Free PMC article. Preprint.
The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy.
Bild AH, Sangar MC, McQuerry JA, Ideker T, Kopetz S, Carey L, Nath A, Marcus D, Regier A, Rashid N, Barzilay R, Winer E, Salgia R, Malhotra J, Gentles A, Buetow K, Mahmood F, Markman DW, Eddy JA; ADAPT Consortium. Bild AH, et al. Cancer Cell. 2026 Mar 9;44(3):449-454. doi: 10.1016/j.ccell.2025.12.008. Epub 2026 Jan 8. Cancer Cell. 2026. PMID: 41512871 Free PMC article.
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.
Pedroza DA, Yuan X, Liu F, Chan HL, Zhang C, Bowie W, Smith AJ, Calderon SJ, Lieu N, Wu W, Porter P, Sarkar P, Zhao N, Oehler CV, Peller O, Gaber MW, Zhu Q, Perou CM, Zhang XH, Rosen JM. Pedroza DA, et al. Among authors: perou cm. Nat Commun. 2026 Jan 3;17(1):1193. doi: 10.1038/s41467-025-67964-2. Nat Commun. 2026. PMID: 41484081 Free PMC article.
631 results